Hyaluronic acid based osteoarthritis therapeutic - Elevate Osteo
Alternative Names: Project DX1Latest Information Update: 19 May 2022
At a glance
- Originator Elevate Osteo
- Developer Hyamedix
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Pain
Most Recent Events
- 25 Apr 2022 Preclinical trials in Inflammation in Australia (Intra-articular)
- 21 Apr 2022 Naris Therapeutics has patent protection pending for hyaluronic acid based osteoarthritis therapeutic (Hyamedix pipeline, April 2022)
- 21 Apr 2022 Preclinical trials in Pain in Australia (Intra-articular)